Spot Ether (ETH) exchange-traded funds experienced net outflows totaling $111 million on October 22, primarily driven by BlackRock's ETHA fund, which alone accounted for $75.45 million of the outflows. This marked a significant increase from the previous day's $29.32 million outflow for ETHA. Meanwhile, Fidelity's FETH fund recorded the largest inflow at $2.37 million. Despite the daily outflows, ETHA's cumulative net inflows remain strong at $12.26 billion, and FETH's total stands at $2.36 billion. Overall, spot Ether ETFs hold $14.57 billion in net assets, representing 5.01% of Ether's total market value, with cumulative net inflows across all funds reaching $12.72 billion. These movements highlight ongoing investor interest and shifts within the Ether ETF market.
Regarding Ether ETFs as of Oct 24, 2026 02:31 WIB, here is Pluang's market snapshot: Among 50 major cryptocurrencies priced on Pluang, 36 rose and 13 fell. Notable movers include LUNC (Terra Classic) at Rp0,832 with a 1-day change of +2.50% and a typical hold time of 195 days, ETC (Ethereum Classic) at Rp141.197 with a 1-day change of +2.19% and 100% buy order activity, and FTM (Fantom) at Rp11.382 with a 1-day change of -2.05%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
